• Login
    • Join
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Manufacturing
    • Markets
    • Top 10
    • Buyers' Guide
    • Events
    • Microsites
    • More
  • Magazine
  • News
  • Exclusives
  • Manufacturing
  • Markets
  • Top 10
  • Buyers' Guide
  • Events
  • Microsites
  • Current & Past Issues
    Features
    Departments
    Columns
    Editorial
    Digital Edition
    Subscribe Now
    Advertise Now
    Editorial Guidelines
    eNewsletter Archive
    eBook
    Top Features
    Additive Manufacturing at the Point of Care

    Six Orthopedic Firms En Route to Significant Market Disruption

    The Next Steps for Recovery and Rehab

    Scratching the Surface: A Roundtable on Coatings and Treatments

    Influencers on the Orthopedic Implant Manufacturing Market
    Breaking News
    Certifications
    Clinical Trials
    Device Approvals & Patents
    Financial & Deals
    International
    Market Data & Trends
    OEM News
    Orthopedic Innovators
    People
    Product & Service Releases
    Products
    Quality, Recalls & Risk
    Regulatory & Legal
    Supplier & Contract Mfg.
    Live From Shows
    Top News & Features
    Integra LifeSciences Founder Dr. Richard Caruso Passes Away

    FDA Clears CTL Amedica's Navigation Instrument System

    FundamentalVR Raises $20 Million in Series B Funding

    Bioventus Achieves Strong Growth in Q2 2022

    Bone Void Fillers Market Growing at 6%
    3-D Printing/Additive Mfg.
    Assembly & Automation
    Biocompatibility & Testing
    Clean Room
    Coatings/Surface Modification
    Contract Manufacturing
    Design
    Extrusion
    Finishing
    Forging & Casting
    Instruments, Cases & Trays
    International/Offshoring
    Laser Processing
    Materials
    Machining & Tooling
    Molding
    Packaging & Sterilization
    Prototyping
    Research & Developement
    Software & Quality
    Staffing, Training & Prof. Dev.
    Supply Chain

    The ODT 2022 Top 10 Orthopedic Device Companies

    Additive Manufacturing at the Point of Care

    Six Orthopedic Firms En Route to Significant Market Disruption

    The Genetic Risk for Joint Replacement Failure

    The Case for Using Historical Control in Clinical Trial Design
    Biologics
    Bracing/Prosthetics
    Extremities
    Imaging
    Instruments
    Large Joint
    MIS/Robotics
    Spine/Neurology
    Trauma/Sports
    Top Markets
    Orthopedic Device Evolution is Driven by Precision Technology

    mdHACM Allografts Demonstrate Potential in Treating Knee Osteoarthritis

    Radically Improving Medicine & Surgery with Light Field Technology

    A Call to Action in Orthopedics: We Need to Personalize Every Single Hip and Knee Surgery

    Giving Knee Replacement Surgery a Much-Needed Update
    Companies
    Categories
    Company Capabilities
    White Papers
    Add New Company
    International Buyers Guide Companies
    Braxton Manufacturing

    AV&R

    Life Science Outsourcing Inc.

    Modern Plastics

    Tiodize
    Industry Events
    Webinars
    • Magazine
      • Current & Past Issues
      • Features
      • Editorial
      • Departments
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • eBook
    • Breaking News
    • Buyers' Guide
      • Companies
      • Categories
      • Company Capabilities
      • White Papers
      • Add Your Company
    • Manufacturing
      • 3-D Printing/Additive Mfg.
      • Assembly & Automation
      • Biocompatibility & Testing
      • Clean Room
      • Coatings/Surface Modification
      • Contract Manufacturing
      • Design
      • Extrusion
      • Finishing
      • Forging & Casting
      • Instruments, Cases & Trays
      • International/Offshoring
      • Laser Processing
      • Materials
      • Machining & Tooling
      • Molding
      • Packaging & Sterilization
      • Prototyping
      • Research & Developement
      • Software & Quality
      • Staffing, Training & Prof. Dev.
      • Supply Chain
    • Markets
      • Biologics
      • Bracing/Prosthetics
      • Extremities
      • Imaging
      • Instruments
      • Large Joint
      • MIS/Robotics
      • Spine/Neurology
      • Trauma/Sports
    • Top 10
    • Online Exclusives
    • Slideshows
    • Videos
    • Webinars
    • Events
      • Industry Events
    • Live from Show Event
    • About Us
      • About Us
      • Contact Us
      • Privacy Policy
      • Terms of Use
      • Advertise With Us
    Columns

    FDA Regulatory Challenges for Antimicrobial Orthopedic Devices

    Preventing and managing orthopedic-associated infections is one of the major challenges in orthopedic surgery.

    FDA Regulatory Challenges for Antimicrobial Orthopedic Devices
    Mehdi Kazemzadeh-Narbat, Ph.D., Associate Director, Regulatory Affairs, MCRA LLC11.17.21
    Orthopedic implants are susceptible to the bacteria attachment and development of infection. Preventing and managing orthopedic-associated infections is one of the major challenges in orthopedic surgery despite the maintenance of strict hygiene protocols and modern surgical techniques. In addition, treating orthopedic infections has become further complicated by the emergence of multi drug-resistant organisms that cannot be managed with traditional antibiotics and prophylaxis. The growth of adhered bacteria to the implant substrate results in the colonization and formation of biofilm, which is up to 1,000 times more resistant than planktonic cells. Bacteria resistance and biofilm formation are the leading causes of orthopedic implant failures. Approximately 14.8 percent of total hip arthroplasty (THA) and 25.2 percent of total knee arthroplasty (TKA) revisions result from infection.1,2 Considering that current U.S. reimbursement models usually do not cover complications like infection, the estimated $100,000 treatment costs for orthopedic infections rests with the patient, physician, hospital, or healthcare service.2,3 The current standard of care for treating acute periprosthetic joint infection is debridement, antibiotics/irrigationa, and implant retention (DAIR) procedure.4

    Strategies for Preventing Infections in Orthopedic Devices
    Several antimicrobial strategies have been applied to prevent infection in joint arthroplasty prostheses, bone void fillers, bone cements, spinal implants, and fracture fixation devices. These strategies mainly are classified into bactericidal or superhydrophobic/anti-fouling.5,6 Bacteriocidal orthopedic devices kill bacteria either upon contact or by releasing antimicrobial agents. The common antimicrobial agents used in orthopedic implants include silver, zinc, copper, nitric oxides, selenium, carbon nanostructures, antibiotics, and polycations like quaternary ammonium compounds, chitosan, and antimicrobial peptides (AMPs).5,7 Superhydrophobic or anti-fouling coating repel or prevent bacteria adherence to the implant surface. For example, modifying the Ti substrate with PEG-based antifouling agent, or certain features such as nanopillars or nano-scale topographies ranging from 20 to 80 nm reportedly may prevent bacteria attachment.8,9 Some recent developing technologies try to eradicate the biofilm through electrical or magnetic forces such as application of cathodic voltage-controlled electrical stimulation,10 or non-invasive high-frequency alternating magnetic fields.11

    FDA Regulatory Challenges
    The industry’s first challenge is to define the regulatory pathway for an orthopedic device with antimicrobial agent. The FDA Office of Combination Products (OCP) assigns the classification based on a product’s primary mode of action (PMOA). According to the OCP, if antimicrobial activity is attributed to physical interaction and does not include chemical or metabolization action, the product is assigned to CDRH as a device. An example of such physical-based antimicrobial activity is antimicrobial properties due to surface topography, anti-fouling, or electrostatic interaction. However, if the PMOA is attributed to the device but the antimicrobial activity associates with chemical action or metabolization, the product is considered a combination product and multiple centers are involved in the review with the CDRH as the lead center. An example of this scenario is the combination of gentamicin with bone void fillers. In case the PMOA is attributable to the antimicrobial component of the combination product, the product is assigned to the Center for Drug Evaluation and Research (CDER) or Center for Biologics Evaluation and Research (CBER) as the lead center with CDRH consultation. An example of this situation is drug delivery systems such as antibiotic beads.

    The major challenge for antimicrobial orthopedic device developers is the huge gap in regulatory science between the industry and FDA. A workshop on orthopedic device-related infections was held on Nov. 13, 2020, in which the agency expressed an unmet need for developing alternatives to the current standard of care for orthopedic infection.12 However, despite recognizing the priority of novel antimicrobial technologies, FDA has not yet recognized sufficient standards or published guidance documents to introduce special controls or provide adequate clear knowledge for establishing antimicrobial safety and effectiveness. 13,14

    From the FDA’s perspective, antimicrobial orthopedic devices face complex challenges in demonstrating safety and effectiveness. It is insufficient for a sponsor to merely provide evidence of in-vitro antimicrobial properties to the FDA. Antimicrobial orthopedic device approval hinges on performing a risk assessment and proposing special controls to address the risks. Generally, coming to an agreement with the agency regarding the risk assessment and special controls occurs through multiple pre-submissions (Q-subs). Some of the risks and challenges that should be addressed through special controls include maintaining antimicrobial activity without impairing biocompatibility; toxicity; developing bacteria resistance; bone growth and osteointegration interference; burst release; lack of stable, steady release over the intended use; ability to disintegrate or eradicate biofilm matrix; and sufficient mechanical stability on the implant surface.5

    Some of the FDA’s more ambiguous expectations are the definitions of antibacterial, antimicrobial, and anti-biofilm. Based on the MCRA’s past interactions, FDA does not consider less than 3 log bioburden reduction of bacteria colony-forming unit (CFU) as an active antibacterial activity, but in some cases up to 6 log reduction has been requested. Another consideration is the proper selection of testing bacteria in accordance with intended use. Since the prevalence of bacteria strains responsible for infection in different devices such as fracture fixation, hip, knee, or spinal implants are dissimilar, the choice of bacteria should be confirmed by the FDA before starting testing. The agency usually recommends companies identify the device’s worst-case scenario and clinically relevant infection to be simulated using resistant forms of at least three Gram-positive and three Gram-negative bacteria. If an antimicrobial claim is made, testing should be expanded to other forms of infection causing pathogens such as fungi. Anti-biofilm claims may require further testing to show the device can disrupt the biofilm matrix and eradicate the planktonic bacteria. For the worst-case scenario of biofilm, companies may be requested to evaluate the challenging forms of biofilm with resistant and persister dormant cells for pre-clinical testing. Moreover, the sponsor should provide the agency with some forms of visual assessment such as scanning electron microscopy (SEM) or confocal microscopy to illustrate the device’s ability to disrupt biofilms.

    Pre-Clinical Testing
    To demonstrate the safety and effectiveness of novel antimicrobial orthopedic devices the FDA recommends adequate in-vitro, in-vivo, or ex-vivo, or clinical data. Because of the complex nature of orthopedic infections, the agency believes bench testing is insufficient and cannot necessarily be translated to in-vivo; therefore, animal study is usually recommended to demonstrate safety and effectiveness. Some recommended in-vitro anti-microbial testing include time-kill test, Agar Disk-Diffusion assay, antimicrobial release profile over time, adhesion testing (e.g., for anti-fouling claims), resistance testing (e.g., Mu50 susceptibility), minimum inhibitory concentration (MIC), and minimum effective concentration (MEC) values determination in accordance with FDA-recognized test methods developed by the Clinical and Laboratory Standards Institute (CLSI) such as M02, M07, and M100.

    There are insufficient guidance documents published by the FDA for antimicrobial medical devices. The only guidance document, published in 2007, “Premarket Notification [510(k)] Submissions for Medical Devices that Include Antimicrobial Agents” has been withdrawn by the Agency. Another FDA guidance document is specific instructions on susceptibility test, “Coordinated Development of Antimicrobial Drugs and Antimicrobial Susceptibility Test Devices.” The agency also appears to accept the unrecognized standard, “ASTM E2149 Standard Test Method for Determining the Antimicrobial Activity of Antimicrobial Agents Under Dynamic Contact Conditions.“

    Biocomaptibility of antimicrobial associated orthopaedic devices is a challenging topic. To demonstrate biocomaptibility, the Agency recommends companies conduct a biological risk assessment in accordance with ISO 10993 series of standards and a 2020 FDA guidance document, “Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process“. The biocomaptibility end points for permanent antimicrobial orthopedic implants include cytotoxicity; sensitization, irritation or intracutaneous reactivity; acute systemic toxicity; material-mediated pyrogenicity; subacute/subchronic toxicity; genotoxicity; implantation; chronic toxicity; and carcinogenicity. For some of these end points (i.e., systemic toxicity as well as genotoxicity and carcinogenicity risks), FDA accepts the use of chemical characterization and toxicological risk assessment approach in accordance with ISO 10993-18, ISO 10993-17, and ISO 21726 in lieu of biological testing. Another safety concern for antimicrobial orthopedic devices is the application of nanoparticles relative to their size and tolerable intake. For example the agency has reported cytotoxicity and adverse effects on the osteogenic differentiation for human bone marrow stem cells at silver nanoparticle concentrations of 10 µg/mL.15 FDA defines the particles with the size range of approximately 1 nanometers(nm) to 100 nm in at least one external dimension, or an internal or surface structure as nanoparticles and believe they may be able to cross biological membrane barriers and have harmful effects due to the potential interaction with organs and cellular compartments. Therefore, their safety assessment including absorption, distribution, metabolism, and excretion parameters should be evaluated. The FDA has published several guidance documents about the application of nanotechnolgy, which can be found on its website.16 

    References
    1. bit.ly/odt112101
    2. bit.ly/odt112102
    3. bit.ly/odt112103
    4. bit.ly/odt112104
    5. bit.ly/odt112105
    6. bit.ly/odt112106
    7. bit.ly/odt112107
    8. bit.ly/odt112108
    9. bit.ly/odt112109
    10. bit.ly/odt112110
    11. go.nature.com/31BVm4F
    12. bit.ly/odt112111
    13. bit.ly/odt112112
    14. bit.ly/odt112113
    15. bit.ly/odt1121114
    16. bit.ly/odt112115


    Dr. Kazemzadeh-Narbat is a former FDA medical device reviewer and joined MCRA in 2020. Dr. Kazemzadeh-Narbat is a biomedical engineer with five years of FDA experience in medical device regulation; he worked at CDRH as a pre-market and post-market lead reviewer of orthopedic and dental devices. At MCRA, he provides guidance on regulatory strategies and submissions development across various therapies.
    Loading, Please Wait..

    Trending
    • MdHACM Allografts Demonstrate Potential In Treating Knee Osteoarthritis
    • Additive Manufacturing At The Point Of Care
    • Bioventus Launches DUROLANE In The U.S.
    • FundamentalVR Raises $20 Million In Series B Funding
    • Future Stars Of The Spine Industry: The Companies To Watch, 2021
    Breaking News
    • Integra LifeSciences Founder Dr. Richard Caruso Passes Away
    • FDA Clears CTL Amedica's Navigation Instrument System
    • FundamentalVR Raises $20 Million in Series B Funding
    • Bioventus Achieves Strong Growth in Q2 2022
    • Bone Void Fillers Market Growing at 6%
    View Breaking News >
    CURRENT ISSUE

    July/August 2022

    • Additive Manufacturing at the Point of Care
    • Six Orthopedic Firms En Route to Significant Market Disruption
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Vitamin K2 May Ameliorate Polycystic Ovary Syndrome
    Vitamin D May Prevent Changes to Liver Enzymes and Lipid Profile After Exhaustive Exercise
    Omega-3 Fatty Acids Linked to Reduced Episodes of Depression
    Coatings World

    Latest Breaking News From Coatings World

    The BEHR & KILZ Brands Partner with Leanne Ford to Revitalize Her Historic American Home
    IGM Resins Acquires Litian
    Ingevity to Acquire Pavement Marking Materials Business, Ozark Materials
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    TransMed7 Achieves First-in-Human for Heron Soft Tissue Biopsy Devices
    West Pharmaceutical Services Invests in Latch Medical
    Integra LifeSciences Founder Dr. Richard Caruso Passes Away
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Societal CDMO Inks Land Sell Deal
    RoosterBio and AGC Biologics to Accelerate Manufacturing of Cell and Exosome Therapies
    WuXi Advanced Therapies Enters Licensing Agreement with Janssen
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Johnson & Johnson to Discontinue Global Sales of Talc-Based Baby Powder
    Dr. Squatch To Launch a 2nd Star Wars Soap Collection
    Neopac Wins 2 European Tube Manufacturers Association Awards
    Happi

    Latest Breaking News From Happi

    Climate Change Drives Sustainability in Household & Personal Care
    Japonesque Acquires Foot Care Brand Barefoot Scientist
    Inolex Launches New Cannabis-Derived Ingredient for Sustainable Conditioning and Emulsification
    Ink World

    Latest Breaking News From Ink World

    Leadership Change in ALTANA’s ELANTAS Division
    Nazdar Highlights Ink Innovation at Labelexpo Americas 2022
    Cyngient, Imageworx Partner at Labelexpo for Security Labeling
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    TLMI partners with Convergen Energy at Labelexpo
    FINAT reports decrease in labelstock consumption during first half of 2022
    Color-Logic partners to feature metallics at autumn events
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Tranzonic Acquired by Private Investment Firm
    Monadnock Earns EcoVadis Gold Rating
    Suominen Announces Price Surcharges
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Integra LifeSciences Founder Dr. Richard Caruso Passes Away
    FDA Clears CTL Amedica's Navigation Instrument System
    FundamentalVR Raises $20 Million in Series B Funding
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    SEMI Appoints John Cooney to Lead Global Advocacy and Public Policy
    NMBS/SNCB Improves Security With HID Global’s Real-Time Location Service Technology
    onsemi Celebrates Expansion of Silicon Carbide Production Facility in New Hampshire

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login